Avalo Therapeutics Financials - Benzinga

Avalo Therapeutics Inc

AVTXNASDAQ

Trade with Public

Trade with Public

$18.64

0.321.72%

Last update: Aug 10, 8:56 AM

Earnings: Q2 2026 Earnings were released on Thu Aug 6th, before the market open

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Avalo Therapeutics Financials

Avalo Therapeutics (AVTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Avalo Therapeutics Q2 EPS $(0.83) Misses $(0.58) Estimate

Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.58) by 43.1 percent. This is a 56.77 percent increase over losses of $(1.92) per share

Benzinga Newsdesk

PRO
Avalo Therapeutics Q1 EPS $(0.98) Beats $(1.13) Estimate

Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.98) per share which beat the analyst consensus estimate of $(1.13) by 13.27 percent. This is a 21.6 percent increase over losses of $(1.25) per share from

Benzinga Newsdesk

Earnings Scheduled For March 23, 2026

Benzinga Insights

PRO
Avalo Therapeutics Q4 EPS $(0.48) Beats $(1.47) Estimate, Sales $59.000K Down From $192.000K YoY

Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(1.47) by 67.3 percent. This is a 127.91 percent decrease over earnings of $1.72 per share

Benzinga Newsdesk

PRO
Avalo Therapeutics Q3 EPS $(2.19) Misses $(1.61) Estimate

Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(2.19) per share which missed the analyst consensus estimate of $(1.61) by 35.6 percent. This is a 22.61 percent increase over losses of $(2.83) per share

Benzinga Newsdesk

PRO
Avalo Therapeutics Q2 EPS $(1.92) Misses $(1.42) Estimate; Cash, Cash equivalents And Short-term Investments Were $113.3M As Of June 30

Avalo Therapeutics (NASDAQ:AVTX) reported quarterly losses of $(1.92) per share which missed the analyst consensus estimate of $(1.42) by 35.5 percent. This is a 86.35 percent increase over losses of $(14.07) per share

Benzinga Newsdesk